ITPD20030264A1 - Metodo di diagnosi altamente specifico per neoplasie - Google Patents

Metodo di diagnosi altamente specifico per neoplasie

Info

Publication number
ITPD20030264A1
ITPD20030264A1 IT000264A ITPD20030264A ITPD20030264A1 IT PD20030264 A1 ITPD20030264 A1 IT PD20030264A1 IT 000264 A IT000264 A IT 000264A IT PD20030264 A ITPD20030264 A IT PD20030264A IT PD20030264 A1 ITPD20030264 A1 IT PD20030264A1
Authority
IT
Italy
Prior art keywords
neoplasia
diagnosis method
highly specific
specific diagnosis
specific
Prior art date
Application number
IT000264A
Other languages
English (en)
Inventor
Luca Beneduce
Giorgio Fassina
Maria Marino
Patrizia Pontisso
Original Assignee
Xeptagen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xeptagen Spa filed Critical Xeptagen Spa
Priority to IT000264A priority Critical patent/ITPD20030264A1/it
Priority to AT04791917T priority patent/ATE557276T1/de
Priority to EP04791917A priority patent/EP1678503B1/en
Priority to EP10182565A priority patent/EP2339345A1/en
Priority to PCT/IT2004/000583 priority patent/WO2005043165A2/en
Priority to EP10178983A priority patent/EP2367005A1/en
Publication of ITPD20030264A1 publication Critical patent/ITPD20030264A1/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
IT000264A 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie ITPD20030264A1 (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IT000264A ITPD20030264A1 (it) 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie
AT04791917T ATE557276T1 (de) 2003-10-30 2004-10-26 Spezifisches verfahren zum krebsnachweis
EP04791917A EP1678503B1 (en) 2003-10-30 2004-10-26 Specific method for cancer detection
EP10182565A EP2339345A1 (en) 2003-10-30 2004-10-26 Method for measuring values indicating cancer
PCT/IT2004/000583 WO2005043165A2 (en) 2003-10-30 2004-10-26 Specific method for cancer detection
EP10178983A EP2367005A1 (en) 2003-10-30 2004-10-26 Method for measuring values indicating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000264A ITPD20030264A1 (it) 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie

Publications (1)

Publication Number Publication Date
ITPD20030264A1 true ITPD20030264A1 (it) 2005-04-30

Family

ID=34531934

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000264A ITPD20030264A1 (it) 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie

Country Status (4)

Country Link
EP (3) EP2367005A1 (it)
AT (1) ATE557276T1 (it)
IT (1) ITPD20030264A1 (it)
WO (1) WO2005043165A2 (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO2007059313A1 (en) * 2005-11-16 2007-05-24 Children's Medical Center Corporation Method to assess breast cancer risk
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP3495000A1 (en) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP2460012B1 (en) * 2009-07-29 2016-04-20 Randox Laboratories Ltd. Method for detection of, or the risk of, bladder cancer
MX337600B (es) 2009-12-02 2016-03-11 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
WO2011085165A2 (en) * 2010-01-08 2011-07-14 The Brigham And Women's Hospital, Inc. Ca-125 immune complexes as biomarkers of ovarian cancer
AU2010365277B2 (en) * 2010-12-06 2017-01-05 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
GB201218570D0 (en) 2012-10-16 2012-11-28 Randox Lab Ltd Method
WO2015117956A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against par1
US10261087B2 (en) 2014-02-04 2019-04-16 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (VEGF)
US10203343B2 (en) 2014-02-04 2019-02-12 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against epidermal growth factor (EGF)
WO2015117955A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against vascular endothelialgrowth factor receptor (vegfr)
US10739346B2 (en) 2014-02-04 2020-08-11 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against EGF-receptor
CN104062437A (zh) * 2014-06-12 2014-09-24 上海交通大学医学院附属瑞金医院 Erbb2蛋白在制备检测嗜铬细胞瘤转移试剂中的应用
EP3230314B1 (en) 2014-12-08 2023-05-03 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
KR20250008141A (ko) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
WO2017201225A1 (en) * 2016-05-19 2017-11-23 Poc Medical Systems, Inc. Cancer screening via detection and quantification of multiple biomarkers
CN106468711A (zh) * 2016-09-07 2017-03-01 北京热景生物技术股份有限公司 Dcp快速分离检测试剂盒
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5915858A (ja) * 1982-07-16 1984-01-26 Otsuka Pharmaceut Co Ltd 腫瘍関連抗原特異的免疫複合体の測定法
US4711839A (en) * 1985-01-11 1987-12-08 Imre Corporation Immune complex assay
EP0529007A1 (en) * 1990-04-18 1993-03-03 The Regents Of The University Of California A 35kD TUMOR ASSOCIATED PROTEIN ANTIGEN: USES AND METHODS OF DETECTION
WO1994008597A1 (en) * 1992-10-14 1994-04-28 The Scripps Research Institute Methods for the detection of antigen-specific immune complexes
WO2001073437A2 (en) * 2000-03-27 2001-10-04 Diagen Corporation Antigen-specific enzyme-linked immunosorbent assay
IT1317355B1 (it) * 2000-07-28 2003-06-16 Xeptagen S R L Anticorpi policlonali.

Also Published As

Publication number Publication date
EP1678503B1 (en) 2012-05-09
EP2339345A1 (en) 2011-06-29
ATE557276T1 (de) 2012-05-15
EP1678503A2 (en) 2006-07-12
WO2005043165A2 (en) 2005-05-12
WO2005043165A3 (en) 2005-08-04
EP2367005A1 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
ATE557276T1 (de) Spezifisches verfahren zum krebsnachweis
CY1112631T1 (el) ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
NO20084546L (no) Diagnostikk og behandlinger for tumorer
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
MA30654B1 (fr) Therapie tumorale avec anticorps anti-vegf
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
CY1109421T1 (el) ΔΟΣΕΙΣ ΓΙΑ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
NO20060843L (no) RG1-antistoffer og anvendelser derav
ATE424560T1 (de) Marker für neuromyelitis optica
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
ATE414535T1 (de) Trägerproteine für impfstoffe
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
DE602005008787D1 (de) Nahrungsmittelanalysator für autonom angetriebene Futterstationen, sowie Verfahren dafür
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
CY1112426T1 (el) Τροποποιητες κανναβινοειδων εξαϋδρο-κυκλοεπταπυραζολης
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2003024304A3 (en) Detection and treatment of cancers of the liver
ATE489624T1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene